Ligand’s Stock Falls as Analysts Debate Value
PHARMA: Co. Confident in Revenue, Cash and Portfolio
By JARED WHITLOCK
NEWS
Ligand Pharmaceutical’s stock has lost more than half of its value since October, puzzling the company and most analysts, though a vocal minority are skeptical of the company’s pipeline.
Market volatility was a factor in Ligand’s stock performance,...
Read latest San Diego Business Journal online.
Online newspapers
at PressDisplay.